Infraredx, which markets a FDA-cleared optical catheter that identifies lipid core coronary plaques, has postponed its planned $56 million IPO. It is the third diagnostics company to postpone an IPO this month, following AltheaDx and AutoGenomics; however, Invitae, which offers genetic testing, priced above the range on February 11 and has gained 24%.
The Burlington, MA-based company was founded in 1998 and booked $5 million in sales for the 12 months ended September 30, 2014. REDX. RBC Capital Markets, Canaccord Genuity and BMO Capital Markets were set to be the joint bookrunners on the deal.
